Pancreatic Cancer Research

ResearcherInsermActive in the last 2 years

Alice Boilève

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0003-3708-4909; OpenAlex author ID A5062924925. Sources: OpenAlex.

Their work

Papers
20 (first author 1, last author 6)
Trials
0
Grants
0
Labs led
1
Collaborators
58
Papers, trials and grants by year

2023: 2 papers · 2024: 6 papers · 2025: 7 papers · 2026: 5 papers

Papers 20

  1. Metastatic pancreatic adenocarcinoma: Real-world efficacy of first line treatment. Last author DOI 10.1016/j.ejca.2025.116160↗
  2. Lung-only metastatic pancreatic cancer: Differences in patients 'characteristics, molecular profile and survival. Co-author DOI 10.1016/j.ejca.2026.116227↗
  3. Development and internal validation of a clinical risk prediction model for pancreatic ductal adenocarcinoma in the UK Biobank. Co-author DOI 10.1016/j.ejca.2026.116767↗
  4. Integrating tumor volumetry and liquid biopsy: a New model to define prognosis in advanced pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.ejca.2026.116768↗
  5. Correction: Identifying health conditions associated with an increased risk of pancreatic ductal adenocarcinoma at medium term in nationwide electronic health … Co-author DOI 10.1038/s41416-026-03597-6↗
  6. Molecular analysis highlights TREM2 as a discriminating biomarker for patients suffering from pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.ctarc.2025.100939↗
  7. Medical management of pancreatic cancer: from personalization to broadening treatment strategies. Co-author DOI 10.1016/j.ctrv.2025.102973↗
  8. Defying the odds: Outstanding survival in lung-only pancreatic cancer treated by Trifluridine-Tipiracil. Last author DOI 10.1016/j.ejca.2024.115125↗
  9. Pan-RAS inhibitor after KRASG12C treatment in pancreatic cancer? Last author DOI 10.1016/j.ejca.2025.115588↗
  10. Precision medicine strategy in pancreatic ductal adenocarcinoma. Last author DOI 10.1016/j.esmoop.2025.105899↗
  11. Identifying health conditions associated with an increased risk of pancreatic ductal adenocarcinoma at medium term in nationwide electronic health records of p… Co-author DOI 10.1038/s41416-025-03172-5↗
  12. The Role of Computed Tomography-Determined Total Tumor Volume at Baseline in Predicting Outcomes of Patients with Locally Advanced Unresectable or Metastatic P… Co-author DOI 10.3390/cancers18010020↗
  13. Clinical and molecular features of early onset pancreatic adenocarcinoma. Last author DOI 10.1002/ijc.35135↗
  14. Olaparib as maintenance therapy in non resectable pancreatic adenocarcinoma associated with homologous recombination deficiency profile: A French retrospective… Co-author DOI 10.1016/j.ejca.2024.115051↗
  15. Codon-specific KRAS mutations predict survival in advanced pancreatic cancer. Co-author DOI 10.1016/j.esmogo.2023.100030↗
  16. Organoids for Functional Precision Medicine in Advanced Pancreatic Cancer. Co-author DOI 10.1053/j.gastro.2024.05.032↗
  17. Pancreatic adenocarcinoma third line systemic treatments: a retrospective cohort study. Last author DOI 10.1186/s12885-024-12016-z↗
  18. Role of molecular biology in the management of pancreatic cancer. Co-author DOI 10.4251/wjgo.v16.i7.2902↗
  19. Efficacy of immune checkpoint inhibitors in microsatellite unstable/mismatch repair-deficient advanced pancreatic adenocarcinoma: an AGEO European Cohort. Co-author DOI 10.1016/j.ejca.2023.04.012↗
  20. Precision Medicine in Pancreatic Ductal Adenocarcinoma: The Impact of Targeted Therapies on Survival of Patients Harboring Actionable Mutations. First author DOI 10.3390/biomedicines11092569↗

Closest collaborators

The 25 strongest of 58 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Michel Pierre Ducreux · 14 shared papers, 2023–2026 · strength 2.99
  2. Antoine Hollebecque · 12 shared papers, 2023–2026 · strength 2.33
  3. Cristina Smolenschi · 11 shared papers, 2023–2026 · strength 2.13
  4. Anthony Tarabay · 10 shared papers, 2023–2026 · strength 1.94
  5. Elie Rassy · 3 shared papers, 2025–2026 · strength 0.90
  6. Maryam Karimi · 3 shared papers, 2025–2026 · strength 0.90
  7. David Malka · 4 shared papers, 2023–2024 · strength 0.65
  8. Fanny Jaulin · 3 shared papers, 2024–2025 · strength 0.63
  9. Antoîne Italiano · 3 shared papers, 2024–2026 · strength 0.52
  10. Anthony Turpin · 3 shared papers, 2023–2025 · strength 0.52
  11. Aurélien Lambert · 2 shared papers, 2024–2026 · strength 0.44
  12. Nathalie Lassau · 2 shared papers, 2025–2026 · strength 0.42
  13. Louis de Mestier · 2 shared papers, 2024–2025 · strength 0.38
  14. Rémy Nicolle · 2 shared papers, 2024–2025 · strength 0.36
  15. Kevin Sarti · 1 shared paper, 2025 · strength 0.33
  16. Léa Swales · 1 shared paper, 2025 · strength 0.33
  17. Julien Taı̈eb · 2 shared papers, 2023–2024 · strength 0.30
  18. Mélanie Debiais · 1 shared paper, 2026 · strength 0.25
  19. Matthieu Delaye · 1 shared paper, 2026 · strength 0.24
  20. Victor Robic · 1 shared paper, 2026 · strength 0.22
  21. Cindy Neuzillet · 1 shared paper, 2025 · strength 0.22
  22. Raphaël Rodriguez · 1 shared paper, 2025 · strength 0.22
  23. Jerome F. Cros · 1 shared paper, 2025 · strength 0.22
  24. Brice Chanez · 1 shared paper, 2025 · strength 0.22
  25. Juan Iovanna · 1 shared paper, 2025 · strength 0.22

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.